Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

A qualitative exploration of digital medicines information usage: Insights from an evaluation of the BNF

Blagden S. et al, (2022), Health Policy and Technology, 11

Obesity: a perfect storm for carcinogenesis.

Harris BHL. et al, (2022), Cancer Metastasis Rev

How Can the EU Beating Cancer Plan Help in Tackling Lung Cancer, Colorectal Cancer, Breast Cancer and Melanoma?

Horgan D. et al, (2022), Healthcare (Basel), 10

Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria.

Larkin J. et al, (2022), Eur J Cancer, 173, 285 - 296

Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis.

Harrison CN. et al, (2022), Future Oncol

Interventions delivered in secondary or tertiary medical care settings to improve routine vaccination uptake in children and young people: a scoping review.

Blagden S. et al, (2022), BMJ Open, 12

A national service for delivering CD19 CAR-Tin large B-cell lymphoma - The UK real-world experience.

Kuhnl A. et al, (2022), Br J Haematol, 198, 492 - 502

CD34+CD19-CD22+ B-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapies.

Bueno C. et al, (2022), Blood, 140, 38 - 44

Rationale and Design of the Cardiac CARE Trial: A Randomized Trial of Troponin-Guided Neurohormonal Blockade for the Prevention of Anthracycline Cardiotoxicity.

Henriksen PA. et al, (2022), Circ Heart Fail, 15

Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial.

Clamp AR. et al, (2022), Lancet Oncol, 23, 919 - 930

A tale of two alleles: TP53 and transformation in MPNs.

Brierley C. and Psaila B., (2022), Blood, 139, 3567 - 3568

Processing single-cell RNA-seq datasets using SingCellaR.

Wang G. et al, (2022), STAR Protoc, 3

Continuous Indexing of Fibrosis (CIF): Improving the Assessment and Classification of MPN Patients

Ryou H. et al, (2022)

Guideline for the first-line management of Classical Hodgkin Lymphoma - A British Society for Haematology guideline.

Follows GA. et al, (2022), Br J Haematol, 197, 558 - 572

In utero origin of myelofibrosis presenting in adult monozygotic twins.

Sousos N. et al, (2022), Nat Med, 28, 1207 - 1211

Management of children and adults with all stages of nodular lymphocyte predominant Hodgkin lymphoma - All StAGEs: A consensus-based position paper from the Hodgkin lymphoma subgroup of the UK National Cancer Research Institute.

Shankar A. et al, (2022), Br J Haematol, 197, 679 - 690

PARPs: All for One and One for All? Enhancing Diversity in Clinical Trials.

Nicum S. and Blagden SP., (2022), Clin Cancer Res, 28, 2201 - 2203

Predicting Survival for Chimeric Antigen Receptor T-Cell Therapy: A Validation of Survival Models Using Follow-Up Data From ZUMA-1.

Vadgama S. et al, (2022), Value Health, 25, 1010 - 1017

VCAM-1-targeted MRI Improves Detection of the Tumor-brain Interface.

Cheng VWT. et al, (2022), Clin Cancer Res, 28, 2385 - 2396

Author Correction: Tumour gene expression signature in primary melanoma predicts long-term outcomes.

Garg M. et al, (2022), Nat Commun, 13

«
...
9
10
11
12
13
14
15
...
»